Brainstorm Cell Therapeutics (NASDAQ:BCLI) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report published on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group upgraded shares of Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 price target for the company in a research note on Thursday, July 11th.

Brainstorm Cell Therapeutics Trading Down 4.2 %

BCLI stock opened at $2.06 on Wednesday. The business’s fifty day moving average price is $0.59 and its 200 day moving average price is $0.51. Brainstorm Cell Therapeutics has a 12-month low of $1.96 and a 12-month high of $11.89. The company has a market capitalization of $144.37 million, a PE ratio of -6.44 and a beta of 0.33.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). During the same quarter last year, the firm posted ($0.27) EPS. Research analysts predict that Brainstorm Cell Therapeutics will post -0.19 EPS for the current fiscal year.

Institutional Trading of Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC acquired a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics at the end of the most recent quarter. 14.33% of the stock is currently owned by institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.